

FIGURE 1




FIGURE 2

Arrows indicate  
use of  $\beta_2$  agonist






FIGURE 3






FIGURE 4



**FIGURE 5**  
**DRB1\*0405/0408 Restriction of FC1P2 Response**  
FC1P2 can be presented to 0408 T cells by 0405 but not 0404



Subject: DRB1\*0408

FIGURE 6

DRB1\*0405 L cells





FIGURE 7




7/16

Subject:DRB1\*0101

Subject:DRB1\*1301

FIGURE 7



Subject:DRB1\*0405



9/16

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V	A
1	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P						
2		R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S					
3			N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T				
4				D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W			
5					C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y		
6						Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V	
7							E	G	H	I	L	K	M	F	P	S	T	W	Y	V	A
8								G	H	I	L	K	M	F	P	S	T	W	Y	V	A
9									H	I	L	K	M	F	P	S	T	W	Y	V	A
10										I	L	K	M	F	P	S	T	W	Y	V	A
11											L	K	M	F	P	S	T	W	Y	V	A
12												K	M	F	P	S	T	W	Y	V	A
13													M	F	P	S	T	W	Y	V	A
14														F	P	S	T	W	Y	V	A
15															P	S	T	W	Y	V	A
16																S	T	W	Y	V	A
17																	T	W	Y	V	A
18																		W	Y	V	A
19																			Y	V	A
20																				V	A
21																					A
22																					
23																					
24																					
25																					
26																					
27																					
28																					

Figure 8 (Sheet 1 of 2). Hypothetical protein (top row) and peptides overlapping by one residue.

10/16

	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	C	L	L	G
1																					
2																					
3																					
4																					
5																					
6																					
7																					
8	R																				
9	R	N																			
10	R	N	D																		
11	R	N	D	C																	
12	R	N	D	C	Q																
13	R	N	D	C	Q	E															
14	R	N	D	C	Q	E	G														
15	R	N	D	C	Q	E	G	H													
16	R	N	D	C	Q	E	G	H	I												
17	R	N	D	C	Q	E	G	H	I	L											
18	R	N	D	C	Q	E	G	H	I	L	K										
19	R	N	D	C	Q	E	G	H	I	L	K	M									
20	R	N	D	C	Q	E	G	H	I	L	K	M	F								
21	R	N	D	C	Q	E	G	H	I	L	K	M	F	P							
22	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S						
23		N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T					
24			D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W				
25				C	Q	E	G	H	I	L	K	M	F	P	S	T	W	C			
26					Q	E	G	H	I	L	K	M	F	P	S	T	W	C	L		
27						E	G	H	I	L	K	M	F	P	S	T	W	C	L	L	
28							G	H	I	L	K	M	F	P	S	T	W	C	L	L	G

Figure 8 (Sheet 2 of 2). Hypothetical protein (top row) and peptides overlapping by one residue.

FIGURE 9 Multiple Overlapping Peptides (MOP)

## Fel d I Chain 1

EICPAVKRDVDLFLTGTPDEYVEQVAQVKALPVVLENARILKNCYDAKNTEEDKENALSLLDKIYTSPLC (SEQ ID No 4)  
 EICPAVKRDVDLFLTGCT (SEQ ID No 6)  
 LFLTGTPDEYVEQVAQY (SEQ ID No 1)  
 EQVAQVKALPVVLENA (SEQ ID No 2)  
 KALPVVLENARILKNCY (SEQ ID No 3)  
 RILKNCYDAKNTEEDKE (SEQ ID No 7)  
 KNTEEDKENALSLLDK (SEQ ID No 8)  
 KENALSLLDKIYTSPL (SEQ ID No 9)

## Fel d I Chain 2

VKMAETCPIFYDVFFAVANGNELLLKLSLTKVNA TEPTAMKKIQDCYVYENGLSRVLDGLVMTTSSSKDCMGEAVQNTVEDLKLNTLGR (SEQ ID No 5)  
 VKMAETCPIFYDVFFA (SEQ ID No 10)  
 CPIFYDVFFAVANGNEL (SEQ ID No 11)  
 GNELLLKLSLTKVNA (SEQ ID No 12)  
 LTKVNA TEPTAMKK (SEQ ID No 13)  
 TAMKKIQDCYVYENGSI (SEQ ID No 14)  
 CYVYENGLSRVLDGLV (SEQ ID No 15)  
 SRVLDGLVMTTSSSK (SEQ ID No 16)  
 ISSSKDCMGEAVQNTV (SEQ ID No 17)  
 AVQNTVEDLKLNTLGR (SEQ ID No 18)

12/16





FIGURE 11



Changes in the cutaneous late phase response to intradermal whole cat dander following intradermal administration of MOP

Figure 12a





Figure 12b



16/16

